Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10406 |
Tuvusertib
M1774,ATR inhibitor 1 |
Apoptosis; ATM/ATR; Others; Chk | Apoptosis; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Others; PI3K/Akt/mTOR signaling |
Tuvusertib (M1774) 是一种可口服的共济失调毛细血管扩张和 Rad3相关(ATR)激酶抑制剂(Ki< 1 µΜ),具有选择性和潜在的抗肿瘤活性。Tuvusertib 选择性抑制 ATR 活性,阻断丝氨酸/苏氨酸蛋白激酶检查点激酶1 (CHK1)的下游磷酸化,从而抑制 DNA 损伤检查点激活,破坏 DNA 损伤修复,诱导肿瘤细胞凋亡。 | |||
T3338 |
Ceralasertib
AZD6738 |
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
Ceralasertib (AZD6738) 是一种具有口服活性的选择性 ATR 激酶抑制剂,IC50 为 1 nM。 | |||
T10468 |
Elimusertib hydrochloride(1876467-74-1 free base)
BAY-1895344 hydrochloride |
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
Elimusertib hydrochloride(1876467-74-1 free base) (BAY-1895344 hydrochloride) 是一种有效的、可口服的、具有抗肿瘤活性的选择性 ATR 抑制剂。 | |||
T79058 | ATR-IN-24 | ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
ATR-IN-24(化合物1)为ATR抑制剂,具备抗肿瘤特性。 | |||
T61808 |
ATR-IN-14
|
||
ATR-IN-14 (compound 1) is a powerful ATR kinase inhibitor that significantly inhibits ATR signaling pathways following CHKI protein phosphorylation, demonstrating a remarkable inhibition rate of 98.03% at 25 nM. Moreover, ATR-IN-14 exhibits notable anticancer efficacy in LoVo cells, displaying an IC50 value of 64 nM [1]. | |||
T10407 |
Gartisertib
ATR inhibitor 2 |
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
ATR inhibitor 2 is an orally active, ATP-competitive, and selective ATR inhibitor (Ki <150 pM) with antitumor activity. ATR inhibitor 2 potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation (IC50: 8 nM). | |||
T79121 |
ATR-IN-29
|
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
ATR-IN-29是一种口服活性的ATR激酶抑制剂,表现出抗增殖活性,其IC50为1 nM。 | |||
T62548 |
ATR-IN-17
|
||
ATR-IN-17 是一种 ATR 激酶的有效抑制剂,在 LoVo 细胞中具有良好的抗癌效果 (IC50: 1 nM)。 | |||
T61587 | ATR-IN-15 | ||
ATR-IN-15 (compound 1) is a highly potent and orally active inhibitor of ATR kinase with an IC50 of 8 nM. Additionally, ATR-IN-15 demonstrates inhibitory activity against several targets, including human colon tumor cells LoVo, DNA-PK, and PI3K, with IC50 values of 47, 663, and 5131 nM, respectively [1]. | |||
T61636 |
ATR-IN-19
|
||
ATR-IN-19 (Compound 15 R-configure) 是一种ATR 抑制剂。 | |||
T61432 |
ATR-IN-16
|
||
ATR-IN-16 (compound 46) is a highly effective ATR kinase inhibitor, exhibiting considerable anticancer activity in LoVo cells, as demonstrated by its IC 50 value of 410 nM [1]. | |||
T78959 | ATR-IN-23 | ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
ATR-IN-23 (Compound 34) 是一种选择性ATR抑制剂,其IC50为 1.5 nM。该化合物对LoVo细胞表现出抗增殖活性,并对HT-29细胞产生合成致死效果,适用于研究DNA损伤反应(DDR)缺陷癌症。 | |||
T79031 |
ATR-IN-21
|
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
ATR-IN-21(化合物60)是一种效力强大的ATR抑制剂,其IC50值小于1000 nM。 | |||
T79033 |
ATR-IN-22
|
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
ATR-IN-22 (Compound 34) 是口服活性ATR抑制剂,能够抑制MIAPaCa-2增殖,IC50值小于1 μM。此外,该化合物在结肠癌研究中展现出抗肿瘤活性。 |